Pulmonary hypertension associated with sarcoidosis

Table 2 Improvement in PAP in patients with sarcoidosis-associated pulmonary hypertension following bosentan treatment

Patient	Initial mean PAP (mmHg)	Follow-up mean PAP (mmHg)	Pulmonary hypertension therapy	Other sarcoidosis medications
1	73	41	Epoprostenol	Prednisone, methotrexate, azathioprine, infliximab
2^a	63	45	Bosentan	Prednisone
3^a	61	ND	Bosentan, epoprostenol	Prednisone, azathioprine
4	53	23	Amlodipine	Prednisone, methotrexate
5	50	ND	Bosentan	Prednisone, methotrexate
6	38	36	Bosentan	Prednisone, methotrexate, azathioprine
7	36	24	Bosentan	Prednisone, methotrexate, infliximab

Shown are data demonstrating improvement in pulmonary artery pressure (PAP) following addition of bosentan to standard anti-inflammatory therapy in a small cohort of patients with sarcoidosis-associated pulmonary hypertension. ^aPatient died. ND, not determined.

ISSN: 1478-6362